Edodekin alfa

Phase 1Biologic

Edodekin alfa is one of 12 biologic programs targeting Metastatic Head and Neck Squamous Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruiting

Metastatic Malignant Solid NeoplasmActive, not recruiting

Metastatic Head and Neck Squamous Cell CarcinomaPreclinical

Active, not recruiting

Metastatic Malignant Solid NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Metastatic Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Taxol

Teva

Phase 2

1 3

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 4

Herceptin

Roche

Phase 1

2 5

Keytruda

Merck & Co.

Phase 1

1 6

Hycamtin

MMeitheal

Preclinical

1 7

Veliparib

AbbVie

Preclinical

1 8

Pidnarulex

NNational Cancer Institute (NCI)

Phase 1

1 9

Edodekin alfa

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Metastatic Malignant Solid Neoplasm

NCT03030378

Q1 2027

PreclinicalActive, not recruiting

Metastatic Head and Neck Squamous Cell Carcinoma

NCT01468896

Clinical

Trials by Indication[1]

Metastatic Malignant Solid Neoplasm1 trial

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03030378·36 enrolled

Metastatic Head and Neck Squamous Cell Carcinoma1 trial

A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT01468896·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Edodekin alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Edodekin alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Edodekin alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Edodekin alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Metastatic Malignant Solid Neoplasm1 trial

Metastatic Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News